Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial - PubMed
6 hours ago
- #MASH treatment
- #digital pathology
- #fibrosis regression
- Resmetirom, a thyroid hormone beta agonist, showed significant improvement in quantitative fibrosis (qFibrosis) metrics compared to placebo in patients with non-cirrhotic MASH.
- AI-based digital pathology (qFibrosis) analysis revealed that resmetirom led to a reduction in continuous qFibrosis values (qFC) and categorical stages (qFS), with up to 24.4% more patients showing improvement than placebo.
- Posthoc assessments identified specific regional collagen features, particularly in portal tract and Zone 2 regions, that correlated strongly with fibrosis progression and were reduced by resmetirom treatment.
- The study highlights the potential of AI-driven quantitative histology to sensitively detect antifibrotic effects and provide more granular insights into fibrosis regression in MASH.